An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Latest Information Update: 26 Dec 2023
At a glance
- Drugs Melphalan (Primary)
- Indications Liver metastases; Uveal melanoma
- Focus Adverse reactions; Expanded access
- Sponsors Delcath Systems
- 20 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 01 Sep 2023 According to Delcath Systems, Inc media release, company announced commercial product available for uveal melanoma patients by the end of 2023 and until that time patients will continue to be enrolled and treated at Expanded Access Program (EAP) sites.
- 01 Sep 2021 New trial record